Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Anti-CD38 mAb Market to Accelerate Substantially During the Study Period (2020-2034)
The anti-CD38 mAb market is set to grow due to strong uptake of DARZALEX and expected entry of SARCLISA subcutaneous formulation, driven by rising cancer and autoimmune disorder diagnoses and increasing clinical trials. DARZALEX dominates with 50% usage in second-line Multiple Myeloma treatment, while SARCLISA trails. Emerging indications include Systemic Lupus Erythematosus and Chronic Kidney Disease. Key companies developing anti-CD38 mAbs are Takeda Pharmaceuticals, HI-Bio, and Genmab. Market dynamics face challenges from biosimilar competition and pricing pressures.
A New Therapy to Prevent or Delay Type 1 Diabetes Now Available at UNC Children's Hospital
UNC Children’s offers Tzield infusions to delay Type 1 diabetes onset, with Nina Jain, MD, and Ali Calikoglu, MD, pivotal in bringing this therapy to NC. Tzield, a 14-day infusion, aims to preserve insulin production and reduce complications, with UNC Children’s being the only NC site providing this care.
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In
Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.
Dengue is spreading and Sanofi is pulling the market's only vaccine. What's next?
Dengue cases have surged globally, with 6.43 million cases and nearly 7,000 deaths in 2023. Sanofi's Dengvaxia, the only FDA-approved dengue vaccine, faces discontinuation due to low demand. Takeda's Qdenga, approved in 40 countries, withdrew its U.S. application. Dengue's spread is exacerbated by climate change and urbanization, with new areas like the U.S. experiencing outbreaks. Vaccine challenges include antibody-dependent enhancement and the need for pre-vaccination screenings. Public health organizations are pushing for more vaccines and treatments.
The Convergence Journey of Research and Care
The 2024 CRAACO conference focused on integrating clinical research into healthcare, emphasizing operational strategies, financial barriers, and expanding access to underserved communities. Highlights included updates on clinical trial integration, virtual models for diverse patient enrollment, and legislative updates on trial diversity.
With activist investment rising, Pfizer's battle with Starboard reflects the industry's post-pandemic challenges
Activist investors, like Starboard Value, are targeting pharma giants such as Pfizer and Novavax, pressuring them to improve performance post-pandemic. This trend reflects broader activism across industries, with investors seeking financial gains and operational changes. Successful activism can drive stock price increases, as seen with Carl Icahn's efforts at Apple and Illumina. For Pfizer, Starboard's involvement highlights dissatisfaction with pandemic-era acquisitions and stock performance, suggesting a need for strategic adjustments. The rise of activist investing underscores the importance of corporate governance and continuous shareholder engagement.
France warns of penalties if Opella production goes offshore
Sanofi in exclusive talks with Clayton Dubilier & Rice to sell a 50% stake in Opella, valued at €16 billion. French government demands production, R&D, management, and workforce remain in France, with €70 million investment commitment. Sanctions include €40 million fine for closing facilities and €100,000 per layoff. France to take 2% stake in Opella. CD&R outbid PAI Partners, raising concerns over job security.
Drug Developers Eying Rollout of AI Legislation in the EU
The EU AI Act, a comprehensive legal framework, will likely influence global AI regulation. It categorizes AI by risk level, with high-risk AI influencing patient lives and requiring strict oversight. The Act aims to ensure AI systems are safe, fair, and protect data privacy, with ongoing discussions on its implementation and impact on innovation.
Sanofi in talks to sell its consumer business Opella; Novo's Rybelsus cut heart risks
Sanofi in talks to sell consumer business Opella; Novo’s Rybelsus reduces heart risks in Phase III trial.
Asthma Drug Companies | Provides Best Medicines
Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.
© Copyright 2025. All Rights Reserved by MedPath